PCYC Share Price

Open 260.76 Change Price %
High 261.68 1 Day 1.70 0.65
Low 260.76 1 Week 0.00 0.00
Close 261.25 1 Month 0.00 0.00
Volume 1953837 1 Year 0.00 0.00
52 Week High 8.48
52 Week Low 4.46
PCYC Important Levels
Resistance 2 262.10
Resistance 1 261.75
Pivot 261.23
Support 1 260.75
Support 2 260.40
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Pharmacyclics, Inc. (NASDAQ: PCYC)

PCYC Technical Analysis 5
As on 22nd May 2015 PCYC Share Price closed @ 261.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 158.90 & Strong Buy for SHORT-TERM with Stoploss of 256.48 we also expect STOCK to react on Following IMPORTANT LEVELS.
PCYC Target for June
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
PCYC Other Details
Segment EQ
Market Capital 3414584320.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.pharmacyclics.com
PCYC Address
PCYC
999 East Arques Avenue
Sunnyvale, CA 94085
United States
Phone: 408-774-0330
Fax: 408-774-0340
PCYC Latest News
Pharmacyclics-AbbVie Merger Has Many Moving Parts   Seeking Alpha   - 13th May 15
Pharmacyclics Reports First Quarter 2015 Financial Results and Provides ...   PR Newswire (press release)   - 01st May 15
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.   PR Newswire (press release)   - 18th Apr 15
Pharmacyclics cancer drug successful as combination therapy: independent panel   Reuters   - 17th Mar 15
The Pharmacyclics And AbbVie Deal Is Good For No One   Seeking Alpha (registration)   - 10th Mar 15
Pharmacyclics Reports Fourth Quarter and Full Year 2014 Financial Results and ...   PR Newswire (press release)   - 19th Feb 15
Pharmacyclics Announces Preliminary 2014 US Net Product Revenue Results and ...   PR Newswire (press release)   - 13th Jan 15
Pharmacyclics: Facts Behind $10B Market Cap   Seeking Alpha   - 04th Feb 14
JPMorgan Healthcare Conference Highlights: Pharmacyclics, Inc.   Motley Fool   - 14th Jan 14
Pharmacyclics Up 45% In The Past 10 Weeks To A New All-Time High   Seeking Alpha   - 28th Sep 13
Interactive Technical Analysis Chart Pharmacyclics, Inc. ( PCYC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Pharmacyclics, Inc.
PCYC Business Profile
Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�s tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.